Zenas BioPharma Inc. ZBIO 深 滬
已收盤 09-12 16:00:00 美东时间
20.23
+0.060
+0.30%
華盛通- 最 高21.72
- 今 開20.14
- 成交量 55.62万股
- 最 低 19.7999
- 昨 收 20.17
- 總市值 8.52亿
- 52周最高 26.2508
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.83
- 委 比 -52.49%
- 總股本 4211.03万
- 歷史最高 26.2508
- 量 比 1.85
- 振 幅 9.52%
- 歷史最低 5.83
- 每 手 1
- 風險率 1.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Zenas BioPharma Secures $300M Funding for Obexelimab
Zenas BioPharma, Inc. ( ($ZBIO) ) just unveiled an update. On September 2, 2025...
09-02 19:50
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
Royalty Pharma will provide up to $300 million to Zenas BioPharma for the development and potential commercial launch of obexelimab, targeting IgG4-Related Disease (IgG4-RD) and other autoimmune diseases. The funding includes $75 million upfront, followed by $75 million upon successful Phase 3 trial results, FDA approval for IgG4-RD, and another $75 million for SLE approval. Obexelimab, a bifunctional monoclonal antibody, is in Phase 3 for IgG4-R...
09-02 11:15
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
<p>Zenas BioPharma, a clinical-stage biopharmaceutical company focused on autoimmune diseases, will present at three investor conferences in September. These include Citi's 2025 Biopharma Back to School Conference on September 2, Cantor Global Healthcare Conference 2025 on September 3, and Morgan Stanley's 23rd Annual Global Healthcare Conference on September 10. The company is dedicated to developing transformative therapies for autoimmune disea...
08-26 11:05
Zenas BioPharma reports Q2 results
Zenas BioPharma, Inc. press release (NASDAQ:ZBIO): Q2 net loss of $52.2 million. The company’s cash, cash equivalents and investments were $274.9 million. The company expects that its cash, cash equiv...
08-12 21:57
Zenas BioPharma Q2 EPS $(1.25) Misses $(1.04) Estimate
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(1.04) by 20.19 percent. This is a 94.84 percent increase over losses of $(24.23) per share
08-12 19:14
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Zenas BioPharma reported updates on its obexelimab trials for autoimmune diseases, including IgG4-RD, Relapsing Multiple Sclerosis (RMS), and Systemic Lupus Erythematosus (SLE). Enrollment for its Phase 3 INDIGO trial in IgG4-RD has been completed, with topline results expected by year-end 2025. The Phase 2 MoonStone trial in RMS achieved enrollment in Q2 2025, with results anticipated early in Q4 2025. The Phase 2 SunStone trial in SLE is on tra...
08-12 11:05
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma, a clinical-stage biopharmaceutical company focused on autoimmune disease therapies, announced that on June 16, 2025, its Compensation Committee granted a non-qualified stock option to a newly hired employee. The option allows the purchase of 112,000 shares with an exercise price of $9.97 per share, equal to the closing price on the grant date. The shares will vest over four years, with 25% vesting after one year and the remainder...
06-20 20:15
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
<p>Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced that its management will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 1:25 p.m. ET. The presentation will be available live and as an archived replay on the Company’s website under "Investor & Media Relations." Zenas is dedicated to developing and commercializing ther...
05-29 11:05
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $30 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $30 price target.
05-16 19:06
